Ultimovacs AS Registered Aktie

0,1644 EUR +0,0032 EUR +1,99 %

14.03.2025

FSE

2,00 NOK +0,01 NOK +0,40 %

14.03.2025

OSL

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.34,86 Mio. EUR

Div. Rendite0,00%

WKNA2PKSD

ISINNO0010851603

SymbolULTMF

Ultimovacs AS Registered Aktien News

Sortieren:Datum Meistgelesen

08.06.23GlobeNewswireUltimovacs ASA: Mandatory notification of trade by primary insider

07.06.23GlobeNewswireUltimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma

10.05.23GlobeNewswireUltimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update

03.05.23GlobeNewswireUltimovacs ASA: Invitation to first quarter 2023 results webcast presentation

25.04.23GlobeNewswireUltimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma

21.04.23GlobeNewswireUltimovacs ASA - Share Option Program

20.04.23GlobeNewswireUltimovacs ASA – Annual General Meeting held on 20 April 2023

14.04.23GlobeNewswireUltimovacs ASA – Disclosure of voting rights of Annual General Meeting

13.04.23GlobeNewswireUltimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations

24.03.23GlobeNewswireUltimovacs ASA: Notice of Annual General Meeting on 20 April 2023

24.03.23GlobeNewswireUltimovacs ASA: Annual Report 2022

27.02.23GlobeNewswireUltimovacs to Present at Cowen Healthcare Conference

16.02.23GlobeNewswireUltimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update

18.10.22GlobeNewswireUltimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility

21.09.22GlobeNewswireUltimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)

12.09.22GlobeNewswireUltimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

09.09.22GlobeNewswireUltimovacs ASA: New share capital registered

05.09.22GlobeNewswireUltimovacs ASA: Mandatory notification of trade by primary insider

05.09.22GlobeNewswireUltimovacs ASA: Share capital increase related to exercise of options

22.08.22GlobeNewswireUltimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent

19.08.22GlobeNewswireUltimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update

18.08.22GlobeNewswireUltimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review

12.08.22GlobeNewswireUltimovacs ASA: Invitation to second quarter 2022 results webcast presentation

30.06.22GlobeNewswireUltimovacs ASA: Mandatory notification of trade by primary insider

30.06.22GlobeNewswireUltimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

20.06.22GlobeNewswireUltimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial

25.05.22GlobeNewswireUltimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy

12.05.22GlobeNewswireUltimovacs ASA: First quarter 2022 result presentation

10.05.22GlobeNewswireUltimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting

05.05.22GlobeNewswireUltimovacs ASA: Invitation to first quarter 2022 results webcast presentation

22.04.22GlobeNewswireUltimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations

21.04.22GlobeNewswireUltimovacs ASA - Share Option Program

21.04.22GlobeNewswireUltimovacs ASA – Annual General Meeting held on 21 April 2022

08.04.22GlobeNewswireUltimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

08.04.22GlobeNewswireUltimovacs ASA – Disclosure of voting rights of Annual General Meeting

30.03.22GlobeNewswireUltimovacs to host Investor Days 2022: Meet the Team

25.03.22GlobeNewswireCorrection: Ultimovacs ASA: Annual Report 2021

25.03.22GlobeNewswireUltimovacs ASA: Notice of Annual General Meeting on 21 April 2022

25.03.22GlobeNewswireUltimovacs ASA: Annual Report 2021

21.03.22GlobeNewswireUltimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma

Ultimovacs AS Registered News

Ultimovacs AS Registered News: auf dieser Seite finden Sie alle Ultimovacs AS Registered News und Nachrichten zur Ultimovacs AS Registered Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ultimovacs AS Registered News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ultimovacs AS Registered News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.